Revolution Medicines, Inc. - Common Stock (RVMD)

Revolution Medicines (RVMD) missed Q2 2025 revenue and EPS estimates, reporting $0 revenue and a -$1.31 loss. Shares dropped 4.5% amid investor concerns, despite progress in Phase 3 trials for daraxonrasib.

Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.

Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.

Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

RVMD stock results show that Revolution Medicines beat analyst estimates for earnings per share the first quarter of 2024.

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.

Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.